KRAS and neoplasm: KRAS G12A scored as the 2nd most significantly underrepresented driver SNV of the 26,361 mutations analyzed in the TCGA and was not observed in any patient tumor sample with any of the four predicted HLA binders in its 35 occurrences (4.3 predicted neoantigen/HLA pairs, Table S5, p = 0.01).